TRDA
Entrada Therapeutics·NASDAQ
--
--(--)
--
--(--)
TRDA fundamentals
Entrada Therapeutics (TRDA) released its earnings on Aug 6, 2025: revenue was 1.95M (YoY -97.94%), missed estimates; EPS was -1.04 (YoY -167.10%), missed estimates.
Revenue / YoY
1.95M
-97.94%
EPS / YoY
-1.04
-167.10%
Report date
Aug 6, 2025
EPS
Actual | -9.78 | -0.89 | -0.69 | -0.74 | -0.8 | -0.79 | -0.21 | -0.78 | 1.02 | -0.29 | 0.68 | 1.55 | -0.35 | 0.03 | -0.42 | -1.04 |
Forecast | -0.87 | -1.285 | -0.655 | -0.725 | -0.76 | -0.8273 | -0.6512 | -0.6898 | -0.735 | -0.1684 | -0.594 | 0.3614 | -0.728 | -0.6698 | -0.7886 | -0.8472 |
Surprise | -1024.14% | +30.74% | -5.34% | -2.07% | -5.26% | +4.51% | +67.75% | -13.08% | +238.78% | -72.21% | +214.48% | +328.89% | +51.92% | +104.48% | +46.74% | -22.76% |
Revenue
Actual | 0 | 0 | 0 | 0 | 0 | 0 | 25.26M | 18.17M | 43.73M | 41.85M | 59.12M | 94.69M | 19.57M | 37.40M | 20.56M | 1.95M |
Forecast | 0 | 0 | 0 | 0 | 0 | 0 | 7.00M | 9.78M | 9.60M | 23.69M | 14.98M | 51.86M | 12.32M | 13.12M | 10.17M | 9.65M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +260.86% | +85.86% | +355.69% | +76.66% | +294.75% | +82.60% | +58.83% | +185.04% | +102.12% | -79.80% |
Earnings Call
You can ask Aime
What is the revenue and EPS growth rate for Entrada Therapeutics year over year?What is Entrada Therapeutics's latest dividend and current dividend yield?What is the market's earnings forecast for Entrada Therapeutics next quarter?What were the key takeaways from Entrada Therapeutics’s earnings call?What is Entrada Therapeutics's gross profit margin?What does Entrada Therapeutics do and what are its main business segments?What were the key takeaways from Entrada Therapeutics's earnings call?What factors drove the changes in Entrada Therapeutics's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
